Observational studyEuropean journal of pediatrics2026
Pediatric adenovirus infections: 10-year clinical spectrum and predictors of severe disease with emphasis on comorbidities and coinfections.
Observational study in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Risk factors for hospitalization in pediatric patients with human adenovirus infection and changes in epidemiological and clinical characteristics before and after the COVID-19 pandemic in China: a multicenter retrospective study.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human adenoviruses (HAdVs) may cause and are responsible for a broad range of pediatric illnesses. Although several cases are self-limiting, certain children may develop complications requiring pediatric intensive care (PICU). To address the role of HAdVs in children, we aimed to characterize the 10-year clinical spectrum of pediatric HAdVs infections and to identify factors associated with hospitalization and severe disease. This retrospective observational cohort study analyzed the clinical course of children (< 18 years) with laboratory-confirmed HAdV infection episodes treated at a tertiary pediatric center between 2014 and 2024. Demographic features, comorbidities, laboratory results, respiratory support requirements, PICU, and clinical outcomes were collected. The severe outcome was defined as a composite endpoint including PICU admission, invasive mechanical ventilation, and/or 30-day mortality. A total of 877 HAdV infection episodes were included, whereas 276 (31.5%) of the patients were hospitalized. Among hospitalized patients, 32.2% required respiratory support, 18.8% required PICU care, and the 30-day mortality was 2.5%. Overall, 104 children (11.9%) developed severe disease. Underlying medical conditions were significantly more frequent among children with severe disease, while those without underlying disease were more common in the non-severe group (69.8% vs. 22.1%; p < 0.001). Viral coinfections were detected in 35.8% of patients but were not associated with increased hospitalization or severity. In multivariable analysis, male sex (OR 2.30, 95% CI 1.23-4.29; p = 0.009), neurologic disease (OR 2.12, 95% CI 1.01-4.42; p = 0.045), cardiac disease (OR 3.27, 95% CI 1.49-7.17; p = 0.003), and hematopoietic stem cell transplantation (HSCT) (OR 4.32, 95% CI 1.36-13.7; p = 0.013) were independently associated with severe outcome.Conclusion: Human adenovirus infection represents a notable clinical burden in children, with a considerable proportion requiring hospitalization and developing severe disease. Underlying neurologic and cardiac diseases, as well as HSCT, were key risk factors for severe outcome, whereas viral coinfections were common but not associated with worse clinical outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.